Why some brain cells are particularly vulnerable to multiple sclerosis – Image for illustrative purposes only (Image credits: Unsplash)
In the gray matter of the brain, where higher thinking and memory take shape, a specific group of neurons faces outsized risk when multiple sclerosis inflammation sets in. Recent research has pinpointed these cells as early casualties, offering fresh clues about how the disease erodes cognitive function over time. The findings shift attention from the more familiar white-matter damage to deeper vulnerabilities in the cortex itself.
Mapping the Most Fragile Cells
A multicenter team from Cedars-Sinai, the University of California, San Francisco, and the University of Cambridge examined brain tissue from people with MS and from animal models that mimic the disease. They discovered that neurons expressing the CUX2 gene, located in the upper layers of the cortex, suffer far more DNA damage than neighboring cells. These neurons normally support complex cognitive tasks, yet they prove especially sensitive once chronic inflammation begins. The pattern held across different models of demyelination and widespread brain inflammation. In each case, the same population of cells showed elevated markers of DNA injury and eventual loss, helping explain the cortical thinning observed in progressive MS.
DNA Damage as the Central Driver
Inflammation does not simply strip away myelin. It triggers a cascade that overwhelms the cells’ ability to repair their genetic material. CUX2 neurons accumulate unrepaired DNA breaks at a rate that outpaces other neurons, leading to dysfunction and death. This selective burden appears intrinsic to the cells rather than solely a result of their location. Researchers confirmed the link by recreating the inflammatory environment in laboratory settings. The same DNA-damage signature emerged, reinforcing that these neurons carry an inherent weakness when exposed to the immune signals that define MS.
Built-in Defenses That Eventually Fail
Even these vulnerable cells possess protective machinery. A gene called ATF4 helps them manage the stress of rapid early development and later inflammatory insults. When researchers removed this safeguard in mouse models, the frontal cortex failed to form properly, underscoring its importance. Under sustained MS-like inflammation, however, the ATF4 response cannot keep pace. DNA damage accumulates faster than repair systems can act, tipping the balance toward cell loss. The result is gray-matter lesions that contribute to the brain shrinkage seen in later stages of the disease.
Early Warnings and New Therapeutic Avenues
David Rowitch, a lead investigator on the studies, described the CUX2 neurons as “like a canary in the coal mine” for the inflamed brain. Their early damage signals trouble ahead and suggests that protecting this population could slow broader decline. Because the cells sit in regions tied to cognition, preserving them might also ease some of the thinking and memory difficulties that many patients experience. The work points toward strategies that bolster DNA-repair pathways or dampen the specific inflammatory signals that hit these neurons hardest. Existing immune-modulating therapies already slow white-matter damage; extending similar protection to gray matter could mark a meaningful advance. Ongoing experiments aim to test whether strengthening the ATF4 pathway or related mechanisms can shield CUX2 neurons before irreversible loss occurs. These insights arrive at a time when MS research increasingly recognizes that gray-matter injury drives much of the long-term disability. By identifying the precise cells at greatest risk and the molecular reasons for their fragility, scientists have opened a clearer path toward interventions that address the disease at its most vulnerable points.